Experimental Pathology Laboratories, Inc. (EPL), and West China-Frontier PharmaTech Co., Ltd. (WCFP) announce a Strategic Alliance to enhance Preclinical Services. This alliance is targeted to bolster the rapid growth of WCFP by specifically providing EPL’s Pathology Peer Review Services for WCFP projects that are being submitted to international regulatory agencies.
WCFP is experiencing rapid growth due to the expanding pharmaceutical and biotechnology sector in China. EPL will assist in this growth by providing pathology peer reviews that are performed by EPL’s highly experienced pathologists, who are board certified by the American College of Veterinary Pathologists. These peer reviews allow for robust pathology reports on projects that will be submitted to the regulatory agencies in Asia, Europe and the United States. These peer reviews also serve as a source of continuing education and training, for both the study pathologist and the reviewing pathologist to meet regulatory requirements.
EPL and WCFP are excited to formally announce this alliance. EPL and WCFP have had an existing business relationship for many years, however, with this strategic alliance both companies seek to continue and expand their collaboration well into the future.
Founded in 1971, EPL is a private, employee-owned US company that is recognized internationally for its ability to meet the needs of the scientific community and the challenges of preclinical safety testing with high quality, on-time histopathology services. Valued for its objectivity and responsiveness, EPL has become industry’s and government’s premier source for expert toxicologic pathology evaluation and consultation.
EPL services are by design more highly focused than the typical full-service Contract Research Organizations (CROs). Consequently, we are able to offer a unique combination of responsive, personal attention and wide breadth of expertise. Our resources include over 100 employees which include highly trained and experienced anatomic veterinary pathologists, toxicologists, histotechnologists, technical personnel and dedicated quality assurance staff. These experts are supported by state-of-the-art laboratories and information technology systems.
Regardless of the location, scope or time-sensitive needs of a study, EPL offers the benefits of a classic personal approach – delivering the highest level of scientific quality in the most cost-effective manner.
WestChina-Frontier PharmaTech (WCFP), or National Chengdu New Drug Safety Evaluation Center, was founded in February 2000 in Chengdu, China. The company is a professional CRO, providing preclinical GLP safety and efficacy evaluations with high quality. The company is OECD, CAP, CFDA-GLP and AAALAC accredited.
WCFP has a staff of 380, including 5 CFDA New Drug Reviewers. WCFP also has a SQARQAP-GLP certified expert, an AAALAC expert, national-class pathologists, and more than 10 experienced study directors and 40 animal technicians.
WCFP has a 16,000 m2 (172,000 sq. ft.) GLP-compliant animal housing facility, enabling it to conduct 130 studies (multiple species) simultaneously. WCFP employs the Pristima® system for electronic data collection and processing, to ensure GLP compliance. WCFP can submit laboratory data to both CFDA and US FDA, and has so far submitted data for over 30 new drugs to the US FDA.